Molecular Composition and Kinetics of B Cells During Ibrutinib Treatment in Patients with Chronic Lymphocytic Leukemia

Sólja Remisdóttir Veyhe(University of Southern Denmark), Charlotte Guldborg Nyvold(University of Southern Denmark), Karen Dybkær(Aalborg University Hospital), Marcus Høy Hansen(University of Southern Denmark), Henrik Frederiksen(University of Southern Denmark), Thor Høyer(Aalborg University Hospital), Karen Juul‐Jensen(University of Southern Denmark), Sara Kamuk Dahlmann(University of Southern Denmark), Niels Abildgaard(University of Southern Denmark), Oriane Cédile(University of Southern Denmark), Michael Møller(Hospital South West Jutland), Mads Thomassen(Odense University Hospital), Jakub Krejcik(University of Southern Denmark)
International Journal of Molecular Sciences
November 22, 2024
10.3390/ijms252312569
Cited by 1

Related Papers

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study
|Leukemia|2011|721
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
|Blood|2013|683
Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
|Journal of Clinical Oncology|2012|682
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders
|The Lancet Oncology|2019|493
Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
|Blood|2012|396